Tieton Capital Management LLC cut its stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) by 50.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 124,338 shares of the company’s stock after selling 126,805 shares during the quarter. Myriad Genetics accounts for approximately 3.7% of Tieton Capital Management LLC’s holdings, making the stock its 15th biggest position. Tieton Capital Management LLC’s holdings in Myriad Genetics were worth $4,270,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Meeder Asset Management Inc. lifted its holdings in shares of Myriad Genetics by 1,067.4% during the third quarter. Meeder Asset Management Inc. now owns 3,292 shares of the company’s stock worth $119,000 after purchasing an additional 3,010 shares during the period. LS Investment Advisors LLC raised its position in Myriad Genetics by 88.5% in the fourth quarter. LS Investment Advisors LLC now owns 4,791 shares of the company’s stock worth $165,000 after acquiring an additional 2,250 shares in the last quarter. Tiedemann Wealth Management LLC raised its position in Myriad Genetics by 67.0% in the third quarter. Tiedemann Wealth Management LLC now owns 13,650 shares of the company’s stock worth $185,000 after acquiring an additional 5,475 shares in the last quarter. Commonwealth Equity Services Inc purchased a new position in Myriad Genetics in the third quarter worth $202,000. Finally, Teacher Retirement System of Texas purchased a new position in Myriad Genetics in the third quarter worth $204,000.
Myriad Genetics, Inc. (NASDAQ:MYGN) opened at $33.34 on Tuesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.05 and a quick ratio of 1.81. The firm has a market capitalization of $2,330.00, a price-to-earnings ratio of 18.12, a PEG ratio of 2.34 and a beta of 0.32. Myriad Genetics, Inc. has a 52-week low of $17.50 and a 52-week high of $41.57.
In other Myriad Genetics news, VP Richard M. Marsh sold 37,654 shares of the firm’s stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $40.25, for a total value of $1,515,573.50. Following the sale, the vice president now directly owns 157,648 shares of the company’s stock, valued at approximately $6,345,332. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Gary A. King sold 3,120 shares of the firm’s stock in a transaction dated Thursday, January 18th. The stock was sold at an average price of $38.12, for a total value of $118,934.40. Following the completion of the sale, the vice president now directly owns 125,088 shares in the company, valued at $4,768,354.56. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 68,033 shares of company stock worth $2,583,197. Corporate insiders own 6.70% of the company’s stock.
Several research analysts have issued reports on MYGN shares. BTIG Research started coverage on Myriad Genetics in a research report on Friday, January 5th. They issued a “buy” rating and a $41.00 price objective for the company. ValuEngine upgraded Myriad Genetics from a “hold” rating to a “buy” rating in a research report on Friday, November 10th. Barclays reiterated a “hold” rating and issued a $30.00 price objective on shares of Myriad Genetics in a research report on Monday, January 8th. Deutsche Bank raised their price target on Myriad Genetics from $28.00 to $30.00 and gave the company a “hold” rating in a research report on Wednesday, November 8th. Finally, Zacks Investment Research cut Myriad Genetics from a “strong-buy” rating to a “hold” rating in a research report on Friday, December 15th. Three analysts have rated the stock with a sell rating, eight have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. Myriad Genetics has a consensus rating of “Hold” and an average price target of $31.42.
COPYRIGHT VIOLATION WARNING: “Tieton Capital Management LLC Sells 126,805 Shares of Myriad Genetics, Inc. (MYGN)” was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/3226281/tieton-capital-management-llc-sells-126805-shares-of-myriad-genetics-inc-mygn.html.
Myriad Genetics Profile
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.
Want to see what other hedge funds are holding MYGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myriad Genetics, Inc. (NASDAQ:MYGN).
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.